Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives

Parasitology International

Volumn 61, Issue 2, 2012, Pages 360-363

  Tavares, Joana ^a,b   Ouaissi, Ali ^a,c   Silva, Ana Marta ^a,b   Lin, Paul Kong Thoo ^d   Roy, Nilanjan ^e   Cordeiro da Silva, Anabela ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSERM   (France)

^d ROBERT GORDON UNIVERSITY   (United Kingdom)

^e NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

BNIP derivatives; In vivo anti Leishmania activity; NAD+ dependent deacetylase inhibitors; SIR2

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; BISNAPHTHALIMIDOPROPYL DERIVATIVE; HEMOGLOBIN; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEISHMANIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ERYTHROCYTE COUNT; HEMATOCRIT; IN VITRO STUDY; LEISHMANIA INFANTUM; LIVER; MALE; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; SPLEEN; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; NAPHTHALIMIDES; PARASITE LOAD; SPLEEN;

LEISHMANIA INFANTUM; MUS;

EID: 84857796039     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2011.11.005     Document Type: Article

References (9)

1. Sundar S., Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian Journal of Medical Research 2006, 123:345-352.
2. Sundar S., Mehta H., Suresh A.V., Singh S.P., Rai M., Murray H.W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clinical Infectious Diseases 2004, 38:377-383.
3. Sindermann H., Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006, 100(Suppl 1):S17-S20.
4. Croft S.L., Seifert K., Yardley V. Current scenario of drug development for leishmaniasis. Indian Journal of Medical Research 2006, 123:399-410.
5. Zhao K., Marmorstein R. Structure of the Sir2 family of NAD+-dependent histone/protein deacetylases. Histone deacetylases: transcriptional regulation and other cellular functions 2006, 203-217. Humana Press Inc., Totowa, NJ. E. Verdin (Ed.).
6. Vergnes B., Sereno D., Tavares J., Cordeiro-da-Silva A., Vanhille L., Madjidian-Sereno N., et al. Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation. Gene 2005, 363:85-96.
7. Tavares J., Ouaissi A., Santarém N., Sereno D., Vergnes B., Sampaio P., et al. The Leishmania infantum cytosolic SIR2 related protein 1 (LiSIR2RP1) is an NAD+-dependent deacetylase and ADP-ribosyltransferase. Biochemical Journal 2008, 415:377-386.
8. Tavares J., Ouaissi A., Kong Thoo Lin P., Loureiro I., Kaur S., Roy N., Cordeiro-da-Silva A. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem 2010, 5:140-147.
9. Buffet P.A., Sulahian A., Garin Y.J., Nassar N., Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrobial Agents and Chemotherapy 1995, 39:2167-2168.